Medical insurance + centralized procurement, the domestic diabetes drug market will open a new phase

Diabetes is a very common chronic disease.
The prevalence of diabetes in China has reached 10.
9%
.
Statistics show that the number of diabetic patients in China currently exceeds 100 million and is predicted to reach 151 million by 2040
.
China attaches great importance to the prevention and treatment of diabetes.
Since diabetes patients need to take medicine for life, in order to reduce the treatment costs of patients, in recent years, centralized drug procurement and medical insurance policies have been vigorous
.
Judging from the situation of hypoglycemic drugs that have been included in the medical insurance catalogue and collected, in addition to imported drugs, the strength of domestic pharmaceutical companies has been continuously improving in recent years, and domestic products have accelerated the replacement of original research
.
In 2016, China's diabetes treatment field ushered in a new breakthrough.
The world's first GLP-1 drug with exactly the same amino acid sequence as human origin, and Shanghai Renhui Biopharmaceutical's Class 1 new drug Benaglutide Injection was approved for marketing.
Has entered the 2020 edition of the National Medical Insurance Negotiation Catalog; In 2017, the world’s first PEGylated long-acting GLP-1 receptor agonist, Hausen’s Class 1 new drug, polyethylene glycol loxenatide injection, was approved for marketing.
It has entered the 2020 National Medical Insurance Catalogue.
Since the injection only needs to be injected once a week, it has greatly improved the convenience and compliance of patients' medication.
After the listing, the sales of public medical institutions in China have also achieved rapid growth
.
At the end of 2018, China officially launched the 4+7 national procurement pilot program, and the fifth batch has been completed.
Many batches of national procurement catalogs all involve diabetes medications, including: the second batch (acarbose, glimepiride) , The third batch (metformin, vildagliptin), the fourth batch (empagliflozin, gliclazide, canagliflozin, nateglinide, repaglinide), the fifth batch (glipizide There are a total of 12 non-insulin hypoglycemic drugs including oxazine, miglitol, and saxagliptin.
In addition, the fifth batch of catalogue also involves lipoic acid, a drug that belongs to other diabetes drugs
.
In the sixth batch of national procurement, insulin, one of the drugs for diabetes treatment, was included as a special collection target.
According to data from Minai.
com, in 2019, China's public medical institutions sold nearly 25 billion yuan of insulin products
.
Through the principle of price-for-quantity, centralized procurement is conducive to reducing the treatment costs of diabetic patients, and at the same time speeds up the pace of domestic substitution of imports
.
According to data, affected by the epidemic, the market size of diabetes medications in China's public medical institutions in the first half of 2021 exceeded 27 billion yuan, a year-on-year decline of 5%
.
However, the market demand for diabetes drugs still has room for growth.
According to the weighted calculation of the market structure of China's diabetes treatment drugs and the year-on-year growth rate in the past three years, the growth rate of China's diabetes treatment drug market is expected to be around 7% from 2020 to 2030.
It will reach 116.
7 billion yuan
.
The industry believes that under the normalization of centralized procurement, drug price reduction has become a trend, and the overall sales scale of diabetes drug products may be reduced.
However, the breakdown of the corporate competition pattern will help newly approved (and over-rated) domestic pharmaceutical companies to quickly seize Market
.
Up to now, the number of diabetes medications that have been reviewed/deemed to be reviewed has reached 34, and there are 7 products that have not been included in the national procurement and have more than 2 companies that have been reviewed, all of which are non-insulin hypoglycemic drugs
.
In addition to the impact of the centralized procurement policy, under the medical protection aviation, the industry believes that domestic innovative drugs will also be able to accelerate the realization of high volume
.
In general, China's diabetes medication market will open a new phase in the future
.